Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-over-year increase for the first nine months of 2025 Financial & Operational Highlights Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million)Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56.7 million)EBITDA for the Group reache ...

Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance Schlieren (Zürich), Switzerland, August 5, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System – a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine procedures. Fo ...